Table 2 Incidence rate of pneumonia.

From: Comparison of pneumonia incidence between long-acting muscarinic antagonist and inhaled corticosteroid plus long-acting beta agonist in patients with COPD

Pneumonia

Unmatched population

Propensity score-matched population

All

LAMA

ICS/LABA

p-value

All

LAMA

ICS/LABA

p-value

Incidence rate per 1000 PYs

102.78

90.20

147.09

< 0.001

112.41

93.96

136.42

< 0.001

Patients with event

812

555

257

 

366

173

193

 

Sum of PYs

7900.29

6153.06

1747.23

 

3256.03

1841.3

1414.73

 

Time to event

 Mean

432.61

446.42

402.79

 

441.61

523.64

368.08

 

 SD

548.35

563.61

513.63

 

568.5

675.18

441.04

 

 Median

257.5

256

265

 

265.5

280

259

 

 Min

2

2

2

 

2

2

2

 

 Max

3481

3481

2995

 

3481

3481

2791

 

 P25

96

96

93

 

103

112

98

 

 P75

495

525

471

 

514

604

437

 

Age (years)

 55 to < 75

90.35

77.90

136.62

< 0.001

100.45

82.37

125.05

0.002

 75+

137.84

126.49

172.47

0.018

143.86

126.66

163.82

0.144

Sex

 Male

100.99

89.96

146.01

< 0.001

114.73

97.85

136.73

0.005

 Female

111.66

91.67

150.17

0.003

104.59

80.80

135.40

0.023

History of COPD exacerbation

 None

95.27

82.78

139.34

< 0.001

105.25

88.78

126.5

0.003

 1 moderate

140.57

122.65

214.09

0.045

142.28

84.91

220.8

0.012

 ≥ 2 moderate OR ≥ 1 severe

149.54

140.35

178.36

0.277

149.82

137.98

165.74

0.506

  1. LAMA long-acting muscarinic antagonists, ICS inhaled corticosteroid, LABA long-acting β2-agonists, PYs Person years, SD standard deviation, COPD Chronic obstructive pulmonary disease.